Performance funds/ETFs
Growth in fund currency
Available documents (NL)
Available documents (EN)
Available documents for this product 
Quote
Quote
€28,16
Quote date
20-05-2026
Performance in EUR
Date
20-05-2026
This year
0,86%
1 week
-3,76%
1 month
-6,51%
3 months
-0,39%
6 months
3,80%
1 year
65,45%
3 years (annualised)
18,44%
5 years (annualised)
-
Since start (annualised)
20,05%
Indicators
Standard deviation (3yr)
24,00%
Share ratio (3yr)
0,81
Beta (3yr)
-
Alpha (3yr)
-
Tracking error (3yr)
-
Top 10 holdings (31-03-2026)
Praxis Precision Medicines Inc Ordinary Shares
6,39 %
Revolution Medicines Inc Ordinary Shares
4,59 %
BridgeBio Pharma Inc
4,34 %
argenx SE ADR
3,98 %
Vertex Pharmaceuticals Inc
3,81 %
United Therapeutics Corp
3,80 %
Gilead Sciences Inc
3,77 %
PTC Therapeutics Inc
3,31 %
Regeneron Pharmaceuticals Inc
3,30 %
Ascendis Pharma AS ADR
3,29 %
Fees
Entry fee
-->Tarievenkaart / Cost information sheet
Exit charges
-->Tarievenkaart / Cost information sheet
Estimated ongoing charges
1,23%
Dividend
Dividend paying
No
Characteristic
Asset Manager
Janus Henderson
Asset class
Equities
Investment category
Equities - Healthcare
Active/Passive
Active
Fund code
212809
Fund code fractional orders
-
Fund manager name
Daniel Lyons|Agustin Mohedas|Andy Acker
ISIN
LU2441283277
Sustainable Classification
Art. 8, ESG integration
Sustainability Rating
Domicile
Luxembourg
Currency
EUR
Fund size (mio)
1.434,63 (20-05-2026)
Cut-off time
-
Execution date
-
Inception date
25-02-2022
Benchmark
NASDAQ Biotechnology TR
Minimum investment amount
-
Assortiment
Self Directed Investing Plus, Investment advice